MCID: TRC008
MIFTS: 53

Trachoma

Categories: Eye diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Trachoma

MalaCards integrated aliases for Trachoma:

Name: Trachoma 12 76 53 55 44 15 73
Trachoma, Initial Stage 73
Trachoma, Active Stage 73
Active Stage Trachoma 12
Trachoma Dubium 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11265
MeSH 44 D014141

Summaries for Trachoma

Disease Ontology : 12 A commensal bacterial infectious disease that results in infection located in eye, has material basis in Chlamydia trachomatis (A, B, Ba and C serovars), which is transmitted by contact with eye discharge from the infected person and transmitted by congenital method. The infection causes eyelid to turn inward which makes eyelashes to scratch the cornea.

MalaCards based summary : Trachoma, also known as trachoma, initial stage, is related to chlamydia and filariasis. An important gene associated with Trachoma is KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3), and among its related pathways/superpathways are NF-kappaB Signaling and Immune response IFN alpha/beta signaling pathway. The drugs Azithromycin and Permethrin have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Trachoma is an infectious disease caused by bacterium Chlamydia trachomatis. The infection causes a... more...

Related Diseases for Trachoma

Diseases related to Trachoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
# Related Disease Score Top Affiliating Genes
1 chlamydia 32.1 HSPD1 IDO1 IL10 TNF
2 filariasis 29.8 IL10 TNF
3 entropion 11.4
4 onchocerciasis 11.4
5 conjunctivitis 10.7
6 inclusion conjunctivitis 10.6
7 ornithosis 10.5
8 lymphogranuloma venereum 10.5
9 yaws 10.3
10 listeriosis 10.2 IDO1 TNF
11 salpingitis 10.2 HSPD1 TNF
12 sympathetic ophthalmia 10.2 HLA-C TNF
13 alveolar echinococcosis 10.1 HLA-C TNF
14 glaucomatocyclitic crisis 10.1 HLA-C TNF
15 geographic tongue 10.1 HLA-C TNF
16 cataract 10.1
17 schistosomiasis 10.1
18 punctate inner choroidopathy 10.1 IL10 TNF
19 tropical endomyocardial fibrosis 10.1 IL10 TNF
20 endomyocardial fibrosis 10.1 IL10 TNF
21 microscopic polyangiitis 10.1 IL10 TNF
22 multifocal choroiditis 10.1 IL10 TNF
23 choroiditis 10.1 IL10 TNF
24 tungiasis 10.1 IL10 TNF
25 transient hypogammaglobulinemia 10.1 IL10 TNF
26 cow milk allergy 10.1 IL10 TNF
27 trichuriasis 10.1 IL10 TNF
28 idiopathic achalasia 10.1 IL10 TNF
29 mucocutaneous leishmaniasis 10.1 IL10 TNF
30 cutaneous leishmaniasis 10.1 IL10 TNF
31 chronic graft versus host disease 10.1 IL10 TNF
32 clonorchiasis 10.1 IL10 TNF
33 autoimmune gastritis 10.1 IL10 TNF
34 autoimmune disease of eyes, ear, nose and throat 10.1 IL10 TNF
35 intermediate uveitis 10.1 IL10 TNF
36 orofacial granulomatosis 10.1 IL10 TNF
37 transverse myelitis 10.1 IL10 TNF
38 post-transplant lymphoproliferative disease 10.1 IL10 TNF
39 primary systemic mycosis 10.1 IL10 TNF
40 mycoplasma pneumoniae pneumonia 10.1 IL10 TNF
41 multidrug-resistant tuberculosis 10.1 IL10 TNF
42 poliomyelitis 10.1 IL10 TNF
43 eales disease 10.1 IL10 TNF
44 hemorrhagic fever 10.1 IL10 TNF
45 echinococcosis 10.1 IL10 TNF
46 spotted fever 10.1 IL10 TNF
47 coccidiosis 10.1 IL10 TNF
48 chronic active epstein-barr virus infection 10.1 IDO1 IL10
49 aseptic meningitis 10.1 IL10 TNF
50 panuveitis 10.1 IL10 TNF

Graphical network of the top 20 diseases related to Trachoma:



Diseases related to Trachoma

Symptoms & Phenotypes for Trachoma

GenomeRNAi Phenotypes related to Trachoma according to GeneCards Suite gene sharing:

26 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.9 HSPD1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.9 KIR2DL2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.9 KIR2DL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.9 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.9 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.9 KIR2DL2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.9 KIR2DL2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.9 HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.9 HSPD1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.9 HSPD1 KIR2DL2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.9 KIR2DL2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.9 HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.9 HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.9 HLA-C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.9 KIR2DL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.9 HSPD1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.9 KIR2DL2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.9 HLA-C
20 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.9 HLA-C
21 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.9 KIR2DL2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.9 KIR2DL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.9 HLA-C
24 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.9 HLA-C
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.9 HLA-C
26 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.9 KIR2DL2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.9 KIR2DL2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.9 HSPD1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.9 HLA-C KIR2DL2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.9 KIR2DL2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.9 HLA-C KIR2DL2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.9 KIR2DL2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.9 HLA-C HSPD1 KIR2DL2

MGI Mouse Phenotypes related to Trachoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.02 ENG HSPD1 IDO1 IL10 TNF

Drugs & Therapeutics for Trachoma

Drugs for Trachoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 83905-01-5 55185 447043
2
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
3
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
4
Albendazole Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54965-21-8 2082
5
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 70288-86-7 6474909
6
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Sulfamethoxazole Approved Phase 4 723-46-6 5329
9 Anti-Infective Agents Phase 4,Phase 3,Not Applicable
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
12 Antiprotozoal Agents Phase 4,Phase 3,Not Applicable
13 Antiparasitic Agents Phase 4,Phase 3,Not Applicable
14 Antimitotic Agents Phase 4,Phase 3,Not Applicable
15 Anthelmintics Phase 4,Phase 3,Not Applicable
16 Antitubercular Agents Phase 4
17 Renal Agents Phase 4
18 Anti-Infective Agents, Urinary Phase 4
19 Antimalarials Phase 4
20 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
21 Immunologic Factors Phase 4
22 Vaccines Phase 4
23
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
24 Ophthalmic Solutions Phase 3,Not Applicable
25 Pharmaceutical Solutions Phase 3,Not Applicable
26 Lipoxygenase Inhibitors Phase 3
27
Fluorometholone Approved, Investigational Not Applicable 426-13-1 9878
28 Lubricant Eye Drops Not Applicable
29 Anti-Inflammatory Agents Not Applicable
30 Anti-Allergic Agents Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Not Applicable
32 Hormones Not Applicable
33 glucocorticoids Not Applicable
34 Hormone Antagonists Not Applicable

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Partnership for Rapid Elimination of Trachoma Completed NCT00792922 Phase 4 Azithromycin;Azithromycin
2 Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Completed NCT00347763 Phase 4
3 Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania Completed NCT00347607 Phase 4
4 Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger Completed NCT00348478 Phase 4
5 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Completed NCT00618449 Phase 4 Azithromcyin;Azithromycin
6 Trachoma Elimination Follow-up Completed NCT00221364 Phase 4 Mass treatment with oral azithromycin to an entire village
7 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4 mass treatment with oral azithromycin
8 Trachoma Amelioration in Northern Amhara (TANA) Completed NCT00322972 Phase 4 Mass treatment with oral azithromycin to an entire community
9 A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Completed NCT00522860 Phase 4
10 Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia Completed NCT00347776 Phase 4 azithromycin;topical tetracycline
11 Mortality Reduction After Oral Azithromycin: Mortality Study Completed NCT02047981 Phase 4 Azithromycin;Placebo
12 Sanitation, Water, and Instruction in Face-washing for Trachoma Recruiting NCT02754583 Phase 4 Azithromycin;Tetracycline;Albendazole
13 Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children Recruiting NCT02414399 Phase 4 Azithromycin;Placebo
14 Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso Active, not recruiting NCT03187834 Phase 4 Azithromycin;Amoxicillin;Cotrimoxazole;Placebo
15 Mortality Reduction After Oral Azithromycin: Morbidity Study Enrolling by invitation NCT02048007 Phase 4 Azithromycin;Placebo
16 Trachoma Elimination Study by Focused Antibiotic (TESFA) Not yet recruiting NCT03523156 Phase 4 Azithromycin mass treatment;Azithromycin targeted treatment
17 Kebele Elimination of Trachoma for Ocular Health Not yet recruiting NCT03335072 Phase 4 Azithromycin
18 Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
19 MORDOR II Burkina Faso Community Not yet recruiting NCT03676764 Phase 4 Azithromycin;Placebos
20 Azithromycin in Control of Trachoma II Withdrawn NCT00286026 Phase 4 Azithromycin
21 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
22 Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Completed NCT00356720 Phase 3 Azithromycin
23 Prevention of Bacterial Infections in Newborn Completed NCT01800942 Phase 3 Azithromycin and Placebo
24 Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death Recruiting NCT03199547 Phase 3 Azithromycin;Placebo Oral Tablet
25 Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Not yet recruiting NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
26 Nepal Elimination of Trachoma Study Withdrawn NCT02176057 Phase 2, Phase 3 Azithromycin
27 Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma Recruiting NCT03813069 Phase 2
28 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial Completed NCT01767506 Not Applicable
29 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis Completed NCT01178762 Not Applicable Azithromycin
30 Modified Instrumentation for Surgery to Correct Trichiasis Completed NCT00886015 Not Applicable
31 Water Uptake for Health in Amhara Pilot Completed NCT02373657 Not Applicable
32 Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination Completed NCT01586169 Not Applicable triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
33 Identification of TT Cases by Community Treatment Assistants: An Assessment Completed NCT01783743 Not Applicable
34 Fluorometholone as Ancillary Therapy for TT Surgery Completed NCT01949454 Not Applicable Fluorometholone 0.1% ophthalmic solution
35 The Effect of Long-Term HEAD START Training on Surgical Skill Levels Completed NCT03135080 Not Applicable
36 A Trial of Epilation Verses Surgery for Minor Trichiasis Completed NCT00522912 Not Applicable
37 Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze Completed NCT00439114
38 Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population Withdrawn NCT02655432

Search NIH Clinical Center for Trachoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: trachoma

Genetic Tests for Trachoma

Anatomical Context for Trachoma

MalaCards organs/tissues related to Trachoma:

41
Eye, Testes, T Cells, Skin, Bone, Heart, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Trachoma:

19
Eye

Publications for Trachoma

Articles related to Trachoma:

(show top 50) (show all 1074)
# Title Authors Year
1
Trachoma in Yunnan province of southwestern China: findings from trachoma rapid assessment. ( 29665861 )
2018
2
Sanitation and water supply coverage thresholds associated with active trachoma: Modeling cross-sectional data from 13 countries. ( 29357365 )
2018
3
Strengthening the links between mapping, planning and global engagement for disease elimination: lessons learnt from trachoma. ( 29907634 )
2018
4
Clinical signs of trachoma are prevalent among Solomon Islanders who have no persistent markers of prior infection with <i>Chlamydia trachomatis</i>. ( 29588922 )
2018
5
Trachoma elimination, approaching 2020. ( 29965850 )
2018
6
Prevalence of trachoma in school children in the MarajA^ Archipelago, Brazilian Amazon, and the impact of the introduction of educational and preventive measures on the disease over eight years. ( 29447155 )
2018
7
Conjunctival transcriptome profiling of Solomon Islanders with active trachoma in the absence of Chlamydia trachomatis infection. ( 29467021 )
2018
8
Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial. ( 29260659 )
2018
9
Detection of Chlamydiaceae and Chlamydia-like organisms on the ocular surface of children and adults from a trachoma-endemic region. ( 29743637 )
2018
10
Patient-centered communication of community treatment assistants in Tanzania predicts coverage of future mass drug administration for trachoma. ( 29329726 )
2018
11
Prevalence of<i>Chlamydia trachomatis</i>-Specific Antibodies before and after Mass Drug Administration for Trachoma in Community-Wide Surveys of Four Communities in Nepal. ( 29141720 )
2018
12
Meibography of Eyes With Sequelae of Trachoma. ( 29504955 )
2018
13
Evaluation of the reproducibility of a serological test for antibodies to Chlamydia trachomatis pgp3: A potential surveillance tool for trachoma programs. ( 29501689 )
2018
14
Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia. ( 29451881 )
2018
15
Correction: Prevalence of Active and Latent Yaws in the Solomon Islands 18 Months after Azithromycin Mass Drug Administration for Trachoma. ( 29513663 )
2018
16
Population-based analysis of ocular Chlamydia trachomatis in trachoma-endemic West African communities identifies genomic markers of disease severity. ( 29482619 )
2018
17
Non-Chlamydial Bacterial Infection and Progression of Conjunctival Scarring in Trachoma. ( 29847638 )
2018
18
Prevalence of trachoma in the Kayes region of Mali eight years after stopping mass drug administration. ( 29432434 )
2018
19
Making gains sustainable: partnering with WASH to stop the transmission of trachoma. ( 29915467 )
2018
20
Baseline trachoma prevalence in Guinea: Results of national trachoma mapping in 31 health districts. ( 29889826 )
2018
21
Chlamydial ompA Diversity in Trachoma-Hyperendemic Communities Treated With Azithromycin. ( 29617922 )
2018
22
Interventions to maximize facial cleanliness and achieve environmental improvement for trachoma elimination: A review of the grey literature. ( 29370169 )
2018
23
Longitudinal change in the serology of antibodies to Chlamydia trachomatis pgp3 in children residing in a trachoma area. ( 29476106 )
2018
24
Association of Chlamydia trachomatis ompA genovar with trachoma phenotypes. ( 29503448 )
2018
25
School-Based versus Community-Based Sampling for Trachoma Surveillance. ( 29848403 )
2018
26
Comment on: 'Association of Chlamydia trachomatis ompA genovar with trachoma phenotypes'. ( 30390052 )
2018
27
Serological and PCR-based markers of ocular Chlamydia trachomatis transmission in northern Ghana after elimination of trachoma as a public health problem. ( 30550537 )
2018
28
Charles Dickens, trachoma, and blindness in pre-Victorian England. ( 29056503 )
2018
29
Models of Trachoma Transmission and Their Policy Implications: From Control to Elimination. ( 29860288 )
2018
30
Quality Assurance and Quality Control in the Global Trachoma Mapping Project. ( 30039782 )
2018
31
Management of trachoma in the Pacific: have we got it wrong? ( 30066471 )
2018
32
A diagnostic instrument to help field graders evaluate active trachoma. ( 30067432 )
2018
33
Coverage of azithromycin mass treatment for trachoma elimination in Northwestern Ethiopia: a community based cross-sectional study. ( 30081851 )
2018
34
Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II). ( 30106956 )
2018
35
An impact evaluation of two rounds of mass drug administration on the prevalence of active trachoma: A clustered cross sectional survey. ( 30157193 )
2018
36
Achieving universal eye health coverage: planning and human resource lessons from trachoma. ( 30220811 )
2018
37
Trachoma prevalence remains below threshold in five districts after stopping mass drug administration: results of five surveillance surveys within a hyperendemic setting in Amhara, Ethiopia. ( 30265355 )
2018
38
Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. ( 30292480 )
2018
39
Identifying a sufficient core group for trachoma transmission. ( 30296259 )
2018
40
Optimising sampling regimes and data collection to inform surveillance for trachoma control. ( 30307939 )
2018
41
Active trachoma among children of District Dera Ghazi Khan, Punjab, Pakistan: A cross sectional study. ( 30317254 )
2018
42
A systematic review of historical and contemporary evidence of trachoma endemicity in the Pacific Islands. ( 30440006 )
2018
43
Behavioural change interventions for sustained trachoma elimination. ( 30455520 )
2018
44
The History of Trachoma and Current Prevalence (Spotlight on Iran): A Review Article. ( 30524975 )
2018
45
Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities. ( 30543311 )
2018
46
The Epidemiology of Trachoma in Mozambique: Results of 96 Population-Based Prevalence Surveys. ( 28910562 )
2017
47
Use of validated community-based trachoma trichiasis (TT) case finders to measure the total backlog and detect when elimination threshold is achieved: a TT methodology paper. ( 28819505 )
2017
48
Active Trachoma Cases in the Solomon Islands Have Varied Polymicrobial Community Structures but Do Not Associate with Individual Non-Chlamydial Pathogens of the Eye. ( 29410954 )
2017
49
Treating village newcomers and travelers for trachoma: Results from ASANTE cluster randomized trial. ( 28662043 )
2017
50
The impact of health promotion on trachoma knowledge, attitudes and practice (KAP) of staff in three work settings in remote Indigenous communities in the Northern Territory. ( 28542225 )
2017

Variations for Trachoma

Expression for Trachoma

Search GEO for disease gene expression data for Trachoma.

Pathways for Trachoma

Pathways related to Trachoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1 12.23 IDO1 IL10 TNF
2
Show member pathways
11.94 HLA-C IL10 TNF
3
Show member pathways
11.93 HLA-C KIR2DL2 KIR2DL3 TNF
4 11.86 HSPD1 IL10 TNF
5
Show member pathways
11.84 HLA-C HSPD1 IL10 KIR2DL2 KIR2DL3 TNF
6 11.79 HSPD1 IL10 TNF
7 11.75 HLA-C KIR2DL2 KIR2DL3
8 11.63 HLA-C KIR2DL2 KIR2DL3
9 11.5 ENG IL10 TNF
10 11.34 ENG TNF
11 11.31 HSPD1 TNF
13 11.21 IL10 TNF
14 11.2 IL10 TNF
15 11.15 HSPD1 IL10
16 11.02 IL10 TNF
17 10.92 IL10 TNF
18 10.68 IDO1 IL10 TNF

GO Terms for Trachoma

Cellular components related to Trachoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 8.92 ENG HLA-C HSPD1 TNF

Biological processes related to Trachoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.79 HSPD1 IDO1 TNF
2 response to drug GO:0042493 9.78 ENG HSPD1 IL10
3 immune response GO:0006955 9.73 HLA-C IL10 KIR2DL3 TNF
4 regulation of immune response GO:0050776 9.71 HLA-C KIR2DL2 KIR2DL3
5 response to lipopolysaccharide GO:0032496 9.65 HSPD1 IDO1 IL10
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.6 IL10 TNF
7 positive regulation of interferon-gamma production GO:0032729 9.59 HSPD1 TNF
8 response to activity GO:0014823 9.58 HSPD1 IL10
9 negative regulation of T cell proliferation GO:0042130 9.58 IDO1 IL10
10 negative regulation of mitotic cell cycle GO:0045930 9.57 IL10 TNF
11 B cell proliferation GO:0042100 9.56 HSPD1 IL10
12 negative regulation of interleukin-6 production GO:0032715 9.55 IL10 TNF
13 positive regulation of cytokine secretion GO:0050715 9.52 IL10 TNF
14 regulation of synapse organization GO:0050807 9.51 IL10 TNF
15 response to organic substance GO:0010033 9.5 HSPD1 IL10 TNF
16 positive regulation of interleukin-12 production GO:0032735 9.49 HSPD1 IDO1
17 positive regulation of macrophage activation GO:0043032 9.46 HSPD1 IL10
18 negative regulation of growth of symbiont in host GO:0044130 9.4 IL10 TNF
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.37 IL10 TNF
20 endothelial cell apoptotic process GO:0072577 9.26 IL10 TNF
21 negative regulation of cytokine secretion involved in immune response GO:0002740 9.16 IL10 TNF
22 response to glucocorticoid GO:0051384 9.13 HSPD1 IL10 TNF
23 receptor biosynthetic process GO:0032800 8.62 IL10 TNF

Sources for Trachoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....